Clinical Research Directory
Browse clinical research sites, groups, and studies.
PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism
Sponsor: Seoul National University Hospital
Summary
This study is a randomized controlled trial to assess the clinical utility of gallium-68 pentixafor PET/CT in the management of primary aldosteronism (PA). We aim to evaluate whether the addition of 68Ga-pentixafor PET/CT to standard adrenal venous sampling (AVS) improves surgical outcomes in patients with unilateral PA.
Official title: A Randomized Controlled Trial to Evaluate the Effect of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Patients With Primary Aldosteronism (The PETAL Trial)
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2025-06-25
Completion Date
2027-12-01
Last Updated
2025-06-18
Healthy Volunteers
No
Conditions
Interventions
68Ga-pentixafor PET/CT
Diagnostic PET/CT imaging using gallium-68 labeled pentixafor to assess adrenal CXCR4 expression in patients with primary aldosteronism. The imaging is performed prior to treatment allocation and used to assist lateralization of aldosterone production when combined with adrenal venous sampling (AVS).
Locations (2)
Samsung Medical Center
Seoul, Gangnam-gu, South Korea
Seoul National University Hospital
Seoul, Jongno-gu, South Korea